PDS Biotechnology Corporation Share Price & Technical Analysis
PDSB · $1.20 (+3.45%)
Healthcare / Biotechnology
$1.20
+3.45%
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101, a Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers. It also develops various product candidates, which are …
Price chart
Seasonality
May has 2 positive and 2 negative years (last 5 years shown)
20% return in May, 16% avg return in past 3 year May month.
64% return in 2026, -64% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 0% | -22% | 0% | 67% | 20% | – | – | – | – | – | – | – | 64% |
| 25 | 0% | -19% | -8% | 17% | 0% | -7% | -15% | 9% | -17% | -10% | -11% | 0% | -61% |
| 24 | 6% | 20% | -40% | -20% | -9% | -3% | 24% | -11% | 19% | -16% | -31% | -27% | -89% |
| 23 | -34% | -8% | -19% | -2% | 57% | -48% | 14% | 4% | -14% | -16% | 26% | -4% | -43% |
| 22 | -27% | 0% | 5% | -11% | -29% | -5% | 16% | 0% | -27% | 73% | 67% | 47% | 109% |
Monthly return % by calendar month · historical pattern, not a forecast
Neutral · Strong · Uptrend
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101, a Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein for treating acute myeloid leukemia, prostate, and breast cancer; and PDS0103 for ovarian, breast, colorectal, and lung cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate, tumor-targeting interleukin 12 immune-cytokine that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, Georgia Research Foundation, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Princeton, New Jersey.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$60.87M
P/E ratio
—
52W high
$1.92
52W low
$0.51
Volume
11,66,996
Beta
1.50
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is PDS Biotechnology Corporation share price today?
- PDS Biotechnology Corporation (PDSB) last traded around $1.20 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does PDSB have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for PDSB. Download the app for real-time alerts.
- How can I analyze PDS Biotechnology Corporation stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.